Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116455 | 0.75 | IFNAR1 (0.42) | CYP1A2CYP2D6ALDH1A1CYP2A6CYP2C19 | |
| SCHEMBL22759066 | 0.69 | HSD17B10 (0.38) | USP2PAK1CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL22753244 | 0.66 | HSD17B10 (0.46) | USP2PAK1CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL2116452 | 0.64 | TSHR (0.44) | USP2PAK1CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL21504652 | 0.63 | IFNAR1 (0.43) | CYP1A2ALDH1A1CYP2A6TSHRHSD17B10 | |
| SCHEMBL22753240 | 0.63 | HSD17B10 (0.38) | USP2PAK1CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL24505626 | 0.62 | TSHR (0.36) | TSHR | |
| SCHEMBL5315813 | 0.61 | POLB (0.42) | ALDH1A1TSHR | |
| SCHEMBL18966732 | 0.61 | HSD17B10 (0.36) | USP2PAK1CYP1A2ALDH1A1CYP2A6 | |
| SCHEMBL1057369 | 0.60 | CYP2A6 (0.46) | USP2PAK1CYP1A2ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10857530-B2 | Olefin metathesis catalysts | UMICORE AG & CO. KG (DE) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857530-B2 | Olefin metathesis catalysts | ZDHHC7, ZDHHC2, OSBP | USP2 3967/4885PAK1 1179/4885HTT 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.